Sercan Aksoy, Medical Oncologist, Breast Cancer and Head and Neck Cancer at Hacettepe University Cancer Institute, shared a post on X:
“In our large Turkish cohort (n=269), T-DXd delivered median PFS 17.9 mo and OS 35.7 mo in HER2+ mBC – consistent with trials, even in real-world LMIC practice. Great to see such robust activity!”
Title: Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study
Authors: Taha Koray Sahin, Fatih Kemik, Harun Muglu, Bedriye Acikgöz Yildiz, Sedat Biter, Salih Tunbekici, Ahmet Oruc, Ali Kaan Guren, Kerim Kaban, Halil Goksel Guzel, Cihan Erol, Musa Baris Aykan, Bahadir Koylu, Omer Burak Ekinci, Ilknur Deliktas Onur, Ali Kalem, Oguz Altunok, Mustafa Seyyar, Bunyamin Guney, Orhun Akdogan, Rashad Ismayilov, Fadime Sinem Ardic, Melike Yazici, Nargiz Majidova, Sema Turker, Ece Esin, Devrim Cabuk, Hatime Arzu Yasar, Arzu Oguz, Ozan Yazici, Riza Umar Gursu, Mesut Yılmaz, Havva Yesil Cinkir, Ozturk Ates, Emir Celik, Nuri Karadurmus, Umut Demirci, Banu Ozturk, Nil Molinas Mandel, Ibrahim Vedat Bayoglu, Murat Araz, Erdem Goker, Ertugrul Bayram, Dilek Erdem, Fatih Selcukbiricik, Gul Basaran, Ahmet Sezer, Gamze Gokoz Dogu, Yasemin Kemal, Ahmet Bilici, Seyda Gunduz, Deniz Can Guven and Sercan Aksoy․
Other articles featuring Sercan Aksoy on OncoDaily.